Diabetes
Conference Coverage
COORDINATE-Diabetes: A ‘wake-up call’ for many specialties
“I look at COORDINATE as a wake-up call to the need for multispecialty approaches to people with type 2 diabetes and cardiovascular disease.”
Conference Coverage
Thirty-three percent of type 1 diabetes patients insulin free with stem cells
Engraftment of Vertex Pharmaceutical’s VX-880 stem cell–derived islets has now been achieved in six patients, two of whom are insulin-independent...
Latest News
WHO plans to declare common sweetener as possible carcinogen
Aspartame would join the “possibly” carcinogenic group, which includes gasoline engine exhaust and working as a dry cleaner.
Commentary
Tirzepatide: Therapeutic titan or costly cure?
Positioning tirzepatide as the first injectable of choice after oral treatment escalation with metformin and an SGLT2 inhibitor may remain an...
Commentary
Beta cells from stem cells: Nearing a cure for type 1 diabetes?
The patients were producing insulin, they had positive C-peptide levels, and it showed that these beta cells work when given to human beings.
Latest News
FDA OKs pancreatic islet cell therapy for type 1 diabetes
“Today’s approval ... provides individuals living with type 1 diabetes and recurrent severe hypoglycemia an additional treatment option to help...
Conference Coverage
Once-weekly basal insulin nears market for type 2 diabetes
“I feel that weekly insulins have the potential to become transformational as preferred options for basal insulin replacement in people with type...
Conference Coverage
ADA: Screen all with type 2 diabetes for fatty liver disease
The ADA now advises screening all adults with type 2 diabetes or prediabetes, particularly those with obesity or cardiometabolic risk factors or...
Latest News
SAFE algorithm detects liver disease in general population
Scoring system was developed and validated to detect clinically significant (greater than stage 2) fibrosis in patients with NAFLD in primary care...
Conference Coverage
Cagrilintide with semaglutide: A way to prevent diabesity?
“These data support further investigation of CagriSema in people with type 2 diabetes in longer and larger phase 3 studies.”
Conference Coverage
OASIS and PIONEER PLUS support high-dose oral semaglutide
OASIS-1 showed that “oral semaglutide 50 mg may represent an effective option for the treatment of obesity, particularly in patients who prefer...